Progestin binding in benign hyperplastic prostatic tissue.
The identification of saturable binding sites for promegestone (17 alpha, 21-dimethyl-19-norpregna-4,9-diene-3,20-dione) in human prostatic cytosol as progesterone receptors is complicated by some differences in binding behaviour between progesterone and promegestone. These differences seem to result from the presence in cytosol of a second class of progestin-binding sites, which has a higher affinity for progesterone than for promegestone.
D001667:Binding, Competitive; D003600:Cytosol / Q000378:metabolism; D006801:Humans; D006854:Hydrocortisone / Q000494:pharmacology; D007700:Kinetics; D008297:Male; D011374:Progesterone / Q000378:metabolism; D011397:Promegestone / Q000378:metabolism; D011467:Prostate / Q000378:metabolism*; D011470:Prostatic Hyperplasia / Q000378:metabolism*; D011980:Receptors, Progesterone / Q000378:metabolism*; D014222:Triamcinolone Acetonide / Q000494:pharmacology
D011980:Receptors, Progesterone; D011374:Progesterone; D011397:Promegestone; D014222:Triamcinolone Acetonide; D006854:Hydrocortisone